METHODS

Design:

randomised controlled trial.

Allocation:

{concealed*}†.

Blinding:

blinded ({data collectors}† and outcome assessors).*

Follow up period:

1 year maintenance phase (after 12 wks in a treatment phase and 16 wks in a continuation phase).

Setting:

12 academic centres in the US.

Patients:

82 patients who were 18–75 years of age (mean age 45 y, 67% women); began the treatment phase with a DSM-IV diagnosis of MDD (duration ⩾2 y) and a score ⩾20 on the 24 item Hamilton Rating Scale for Depression (HRSD-24); and responded to CBASP alone during the treatment …